Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

SciSparc Ltd. - Ordinary Shares (NQ:SPRC)

0.3178 -0.0002 (-0.06%)
Streaming Delayed Price Updated: 11:04 AM EDT, Jun 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about SciSparc Ltd. - Ordinary Shares

< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
SciSparc and Clearmind Reveal Three Unique Combinations of Future Psychedelic-Based Compounds
Clearmind Medicine submitted patent applications to protect the novel compounds 
From SciSparc Ltd
Via GlobeNewswire
Israel-Based Clearmind Medicine Files Patent Applications for Three Unique Combinations of Future Psychedelic-Based Compounds
From Clearmind Medicine Inc.
Via GlobeNewswire
Why CVRx Shares Are Trading Lower By 43%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Arbe Robotics Ltd. (NASDAQ: ARBE) gained 62.8% to $7.08. Arbe Robotics is expected to report its financial results for the fourth quarter on Thursday, March 2, 2023. 
Via Benzinga
Why Owlet Shares Are Trading Higher By Over 45%; Here Are 20 Stocks Moving Premarket
Gainers Troika Media Group Inc (NASDAQ: TRKA) shares rose 65.9% to $0.37 in pre-market trading after dropping 4% on Friday. 
Via Benzinga
Why Universal Electronics Shares Are Trading Lower By 30%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers Ibio Inc (NYSE: IBIO) shares rose 97% to $1.4787 after the company announced MUC16 as its latest immune-oncology target program. 
Via Benzinga
Jeffs' Brands Joins Hand With SciSparc For New Line Of Products
Via Benzinga
Why SciSparc Shares Are Moving During Friday's Session
SciSparc Ltd (NASDAQ: SPRC) shares are trading higher by 8.08% to $0.98 Friday morning, though off the session high of $1.33, after the company announced its MitoCareX Bio joint venture achieved... 
Via Benzinga
Why Is SciSparc (SPRC) Stock Up 14% Today?
SciSparc (SPRC) stock is taking off on Friday as investors react to an update on its drug development joint venture MitoCareX Bio. 
Via InvestorPlace
SciSparc's Drug Discovery Joint Venture MitoCareX Bio Successfully Reached First Milestone for its Future Machine Learning System
From SciSparc Ltd
Via GlobeNewswire
Novel Combination Of Cannabis-Like Compound With Classical Psychedelics Searches IP Coverage In US
Israeli-based next-gen psychedelics biotech Clearmind Medicine (NASDAQ: CMND) together with partner clinical-stage pharma company SciSparc (NASDAQ: SPRC) has filed three provisional patent applications... 
Via Benzinga
SciSparc and Clearmind Collaboration Strengthens IP Portfolio with Three Provisional Patent Applications in the US
From SciSparc Ltd
Via GlobeNewswire
Israel-Based Clearmind Medicine Strengthening IP Portfolio with Three Provisional Patent Applications in the US
From Clearmind Medicine Inc.
Via GlobeNewswire
Why Grom Social Enterprises Shares Are Trading Lower By 30%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA) shares surged 85% to $2.2200. Sonoma Pharmaceuticals and EMC Pharma announced Department of Defense DAPA registration for Microcyn(R) Rx products. 
Via Benzinga
SciSparc Announces Corporate Restructuring plan
From SciSparc Ltd
Via GlobeNewswire
Why Evoqua Water Technologies Shares Are Trading Higher By 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Intelligent Bio Solutions Inc. (NASDAQ: INBS) shares climbed 444.4% to $1.47 after the company announced it successfully completed the review of results from Milestone 7, a phase of its... 
Via Benzinga
SciSparc to Investigate and Evaluate Concerns of Illegal Trading of its Ordinary Shares
From SciSparc Ltd
Via GlobeNewswire
Envisioning A Cocaine-Addiction Treatment: This Next-Gen Psychedelic Shows Positive Results
Israel-based psychedelics biotech Clearmind Medicine Inc. (NASDAQ: CMND) shared additional positive results on the impact of the MEAI molecule in the natural reward process in an in-vivo preclinical... 
Via Benzinga
SciSparc Receives Approval to Conduct its Clinical Trial in Children with Autism Spectrum Disorder at the Soroka Medical Center
From SciSparc Ltd
Via GlobeNewswire
SciSparc Announces Additional Positive Results from the Third Part of Clearmind Medicine Inc. Pre-Clinical Study for Cocaine Addiction Treatment
From SciSparc Ltd
Via GlobeNewswire
This Pharma Company Is Working With Israeli Medical Center To Research And Treat Autism With CBD
SciSparc Ltd. (NASDAQ: SPRC), a pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced it has signed an agreement with the Soroka... 
Via Benzinga
SciSparc Signs Agreement to Conduct its Clinical Trial in Autism Spectrum Disorder with Soroka Medical Center
From SciSparc Ltd
Via GlobeNewswire
This Original Psychedelic-Based Obesity Treatment Set To First-In-Human Trials
Psychedelics biopharma company Clearmind Medicine Inc. (NASDAQ: CMND) and clinical-stage firm SciSparc Ltd. 
Via Benzinga
SciSparc Ltd. Announces Efficacy of Psychedelic-Based Obesity Treatment of Clearmind Medicine Inc. in Pre-Clinical Trial
From SciSparc Ltd
Via GlobeNewswire
SciSparc Signs LOI to Sell 50% Interest in Subsidiary
SciSparc Ltd. (NASDAQ: SPRC) announced that it has entered into a non-binding letter of intent ("LOI") for the sale of a 50% interest in its wholly owned subsidiary, SciSparc Nutraceuticals Inc. 
Via Benzinga
SciSparc Signs Non-Binding LOI To Sell A 50% Interest In Its Subsidiary That Owns Wellution
SciSparc Ltd. (NASDAQ: SPRC) has entered into a non-binding letter of intent for the sale of a 50% interest in its wholly owned subsidiary, SciSparc Nutraceuticals Inc., which owns Wellution, to Jeffs'... 
Via Benzinga
SciSparc Enters Into Non-Binding Letter of Intent to Sell a 50% interest in its Subsidiary that Owns an Amazon Top Seller Brand
From SciSparc Ltd
Via GlobeNewswire
SciSparc Announces Positive Study Results with SCI-210, a Cannabidiol-Based Treatment for Epilepsy
From SciSparc Ltd
Via GlobeNewswire
SciSparc Regains Compliance with Nasdaq Minimum Closing Bid Price Rule
From SciSparc Ltd
Via GlobeNewswire
SciSparc Enters Into Letter of Intent with an E-commerce Company to Establish a Joint Venture to Market and Develop a New Product Line
From SciSparc Ltd
Via GlobeNewswire
SciSparc Gains Competitive Edge with Additional U.S. Patent Granted
From SciSparc Ltd
Via GlobeNewswire
< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.